Liver disease management focuses on lifestyle and new medications

Metabolic dysfunction-associated steatotic liver disease (MASLD) is identified as the most common chronic liver disease globally, affecting nearly 30 percent of the adult population and approximately 10 percent of children. Experts note that prevalence may be underestimated due to the asymptomatic nature of the disease and a lack of widespread screening.

Medical professionals emphasize that treatment primarily relies on lifestyle modifications. Key strategies include weight reduction, which can potentially reverse liver steatosis and early-stage fibrosis, and dietary changes. Recommended nutritional approaches include consuming easily digestible carbohydrates, adjusting protein intake to one or two grams per kilogram of body weight, and limiting fats to 40–60 grams daily, preferably from plant sources. Specific beneficial foods include cruciferous vegetables, leafy greens, berries, and omega-3 rich fish.

In addition to lifestyle changes, clinical advancements have led to the approval of specific medications for patients with metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis (F2–F3), specifically resmetirom and semaglutide.